ReviewQatar medical journal2026
Breaking barriers: A decade-long institutional journey to sustain mandated living kidney-donor follow-up in Qatar.
Review in Qatar medical journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Living kidney donation is essential for expanding transplant opportunities, given the worldwide scarcity of deceased donor organs. Kidney donors experience a slight but detectable long-term increase in risks such as hypertension, diabetes, and end-stage kidney disease, making sustained follow-up essential. However, adherence to post-donation surveillance remains inconsistent worldwide. Methods: This descriptive evaluation included living kidney donors enrolled in Qatar's national follow-up program at Hamad Medical Corporation, implemented in January 2017. The program mandates nephrology follow-up at 1 and 6 months post-donation and annually thereafter, with standardized clinical and laboratory monitoring. Adherence rates from 2017 to 2024 were assessed against institutional benchmarks (>90%). Results: Of 349 registered donors nationwide, 233 donated after program implementation. Despite a fourfold increase in eligible donors between 2017 and 2024, 1- and 6-month follow-up rates remained near 100%, and annual adherence consistently exceeded 90% from 2020 onward. Compliance with the nephrologist-led review of clinical and laboratory data approached 100% among attendees. Sustained performance was temporally associated with system-level interventions, including coordinator-led outreach, structured process redesign, enhanced donor education, and continuous quality improvement initiatives. Follow-up rates also remained robust during the COVID-19 pandemic despite the transition to telephone-based consultations. Conclusion: A centralized, quality-driven national framework can achieve durable, high-level adherence to long-term follow-up among living kidney donors, even amid rapid program expansion. This scalable model provides a strong foundation for registry-based outcome monitoring and evidence-informed donor care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.